Head-to-head evidence
Eculizumab vs Ravulizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Complement C5 · full Chronic Kidney Disease pipeline
Eculizumab · Soliris
Marketed by AstraZeneca
NCT01567085 · Phase 2 · completed
All 80 participants received eculizumab with no randomization, blinding, or concurrent control group; the low treatment-failure rate was compared only to a fixed benchmark rate rather than to a comparator arm enrolled in the same trial, so it cannot on its own establish the drug's effect.
Ravulizumab · Ultomiris
Marketed by AstraZeneca
NCT05746559 · Phase 3 · terminated
This is a randomized, double-blind, placebo-controlled trial with a clinically defined kidney-injury outcome, which is a strong design. The study was terminated: ClinicalTrials.gov records that it was discontinued on 29 April 2026 for lack of efficacy in the study population. No results are posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eculizumab's landscape · Ravulizumab's landscape